Australian biotech company Immutep (ASX: IMM, NASDAQ: IMMP) has delivered impressive Phase I clinical trial results for its TACTI-mel trial…
Labourers and athletes prone to shoulder injuries could have a significant solution after 89% of patients participating in Orthocell’s (ASX:…